^
Association details:
| Biomarker: | PIK3CA E545K |
|---|---|
| Cancer: | Breast Cancer |
| Drug: | Herceptin (trastuzumab) (HER2 inhibitor) + lapatinib (EGFR inhibitor, HER2 inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVP-BEZ235
Excerpt:
Interestingly, expression of PIK3CA (E545K) and PIK3CA (H1047R) also conferred resistance to the growth arrest conferred by the combined treatment of lapatinib and trastuzumab.
DOI:
10.1158/0008-5472.CAN-08-1740
